扶正解毒方联合免疫检查点抑制剂对气阴两虚型晚期非小细胞肺癌患者的影响OA
Effects of Fuzheng Jiedu Formula Combined with Immune Checkpoint Inhibitors on Patients with Advanced Non-Small Cell Lung Cancer of Qi and Yin Deficiency Type
目的:观察扶正解毒方联合免疫检查点抑制剂(卡瑞利珠单抗)对气阴两虚型晚期非小细胞肺癌(NSCLC)患者免疫功能、肺功能、生存质量及肿瘤标志物的影响.方法:选择符合纳入标准的196例气阴两虚型晚期NSCLC患者,依据随机数字表随机分为对照组和研究组,每组各98例.两组均给予常规化疗,对照组在常规化疗的同时给予免疫检查点抑制剂治疗,研究组在常规化疗的同时给予扶正解毒方联合免疫检查点抑制剂治疗,21 d为1个治疗周期,两组均治疗4个周期.比较两组治疗前后免疫功能、肺功能、生存质量(QLO-C30)评分、血清肿瘤标志物的变化情况,同时比较临床疗效和不良反应发生率.结果:等级资料秩和检验显示,研究组治疗后临床疗效和总有效率明显高于对照组(P<0.05).治疗后,两组患者CD3+、CD4+水平及CD4+/CD8+比值均较治疗前降低(P<0.05),CD8+水平升高(P<0.05),且研究组CD3+、CD4+及CD4+/CD8+低于对照组,CD8+高于对照组(P<0.05);治疗后,两组第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、呼气峰流速值(PEF)、最大通气量(MVV)均较治疗前显著提升(P<0.05),且研究组高于对照组(P<0.05);治疗后,两组QLO-C30各维度评分显著提升(P<0.05),且研究组QLO-C30各维度评分均高于对照组(P<0.05);治疗后,两组患者血清中癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、血管内皮生长因子(VEGF)水平均较治疗前显著降低(P<0.05),且研究组较对照组降低更明显(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:扶正解毒方联合免疫检查点抑制剂治疗气阴两虚型晚期非小细胞肺癌疗效显著,可有效改善免疫功能,提高肺功能与生存质量,调节肿瘤标志物水平,且安全性高.
Objective:To observe the effects of Fuzheng Jiedu Formula combined with immune checkpoint inhibitors(camrelizumab)on immune function,lung function,quality of life,and tumor markers in patients with Qi and Yin deficiency type advanced non-small cell lung cancer(NSCLC).Methods:A total of 196 patients with Qi and Yin deficiency type advanced NSCLC meeting the inclusion criteria were randomly divided into a control group and a study group,with 98 patients in each group.Both groups received conventional chemotherapy.The control group was treated with immune checkpoint inhibitors alongside chemotherapy,while the study group was treated with Fuzheng Jiedu Formula combined with immune checkpoint inhibitors alongside chemotherapy.Each treatment cycle lasted 21 days,and both groups were treated for four cycles.Changes in immune function,lung function,quality of life(QLO-C30 scores),and serum tumor markers before and after treatment were compared between the two groups,as well as clinical efficacy and the incidence of adverse reactions.Results:Rank-sum test of ordinal data showed that the clinical efficacy and total effective rate in the study group were significantly higher than those in the control group after treatment(P<0.05).After treatment,CD3+,CD4+levels,and the CD4+/CD8+ratio decreased significantly(P<0.05),while CD8+levels increased(P<0.05)in both groups.These changes were more pronounced in the study group compared to the control group(P<0.05).Post-treatment,forced expiratory volume in 1 second(FEV1),forced vital capacity(FVC),peak expiratory flow(PEF),and maximum voluntary ventilation(MVV)were significantly improved in both groups(P<0.05),with greater improvements observed in the study group(P<0.05).QLO-C30 scores for all dimensions significantly increased in both groups(P<0.05),with higher scores in the study group compared to the control group(P<0.05).Serum levels of carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1),and vascular endothelial growth factor(VEGF)were significantly reduced in both groups(P<0.05),with a more pronounced reduction in the study group(P<0.05).The incidence of adverse reactions did not significantly differ between the two groups(P>0.05).Conclusion:Fuzheng Jiedu Formula combined with immune checkpoint inhibitors is effective in treating Qi and Yin deficiency type advanced NSCLC,significantly improving immune function,lung function,quality of life,and tumor marker levels,with high safety.
王振;郭宗尚;孙亚飞
驻马店市中心医院,河南 驻马店 463000驻马店市中心医院,河南 驻马店 463000驻马店市中心医院,河南 驻马店 463000
非小细胞肺癌气阴两虚型扶正解毒方免疫检查点抑制剂
Non-small cell lung cancerQi and Yin deficiency typeFuzheng Jiedu FormulaImmune checkpoint inhibitors
《中医药信息》 2025 (2)
52-57,6
河南省医学科技攻关计划项目(LHGJ20220194)
评论